Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations

v3.22.1
Consolidated Statements of Operations - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Operating expenses:    
Research and development $ 197,568 $ 108,741
Selling, general and administrative 61,521 23,495
Total operating expenses 259,089 132,236
Loss from operations (259,089) (132,236)
Interest and other income, net 1,148 5,649
Interest expense (2,426) (249)
Income from equity method investment 29,405 5,799
Gain on deconsolidation of subsidiary 0 6,904
Transaction expenses related to merger (9,087) 0
Gain from change in fair value of warrants and earnout shares 49,853 0
Convertible note extinguishment loss (665) 0
Total other income, net 68,228 18,103
Loss before income taxes (190,861) (114,133)
Income tax expense (benefit) (10,537) 31
Net loss $ (180,324) $ (114,164)
Net loss per share, basic and diluted $ (0.61) $ (1.10)
Weighted-average common shares outstanding, basic and diluted 294,851,732 103,946,993